Minimal Detectable Changes of the Health Assessment Questionnaire–Disability Index, Patient-Reported Outcomes Measurement Information System-29 Profile Version 2.0 Domains, and Patient Health Questionnaire-8 in People With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Cross-Sectional Study

IF 3.7 2区 医学 Q1 RHEUMATOLOGY Arthritis Care & Research Pub Date : 2024-06-26 DOI:10.1002/acr.25397
Afra Alkan, Marie-Eve Carrier, Richard S. Henry, Linda Kwakkenbos, Susan J. Bartlett, Amy Gietzen, Karen Gottesman, Geneviève Guillot, Amanda Lawrie-Jones, Marie Hudson, Laura K. Hummers, Vanessa L. Malcarne, Maureen D. Mayes, Luc Mouthon, Michelle Richard, Robyn K. Wojeck, Maureen Worron-Sauvé, Andrea Benedetti, Brett D. Thombs, the Scleroderma Patient-Centered Intervention Network Investigators
{"title":"Minimal Detectable Changes of the Health Assessment Questionnaire–Disability Index, Patient-Reported Outcomes Measurement Information System-29 Profile Version 2.0 Domains, and Patient Health Questionnaire-8 in People With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Cross-Sectional Study","authors":"Afra Alkan,&nbsp;Marie-Eve Carrier,&nbsp;Richard S. Henry,&nbsp;Linda Kwakkenbos,&nbsp;Susan J. Bartlett,&nbsp;Amy Gietzen,&nbsp;Karen Gottesman,&nbsp;Geneviève Guillot,&nbsp;Amanda Lawrie-Jones,&nbsp;Marie Hudson,&nbsp;Laura K. Hummers,&nbsp;Vanessa L. Malcarne,&nbsp;Maureen D. Mayes,&nbsp;Luc Mouthon,&nbsp;Michelle Richard,&nbsp;Robyn K. Wojeck,&nbsp;Maureen Worron-Sauvé,&nbsp;Andrea Benedetti,&nbsp;Brett D. Thombs,&nbsp;the Scleroderma Patient-Centered Intervention Network Investigators","doi":"10.1002/acr.25397","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>Systemic sclerosis (SSc) is a rare, chronic autoimmune disorder associated with disability, diminished physical function, fatigue, pain, and mental health concerns. We assessed minimal detectable changes (MDCs) of the Health Assessment Questionnaire–Disability Index (HAQ-DI), Patient-Reported Outcomes Measurement Information System-29 Profile version 2.0 (PROMIS-29v2.0) domains, and Patient Health Questionnaire (PHQ)-8 in people with SSc.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Scleroderma Patient-Centered Intervention Network Cohort participants completed the HAQ-DI, PROMIS-29v2.0 domains, and PHQ-8 at baseline assessments from April 2014 until August 2023. We estimated MDC95 (smallest change that can be detected with 95% certainty) and MDC90 (smallest change that can be detected with 90% certainty) with 95% confidence intervals (CIs) generated via the percentile bootstrapping method resampling 1,000 times. We compared MDC estimates by age, sex, and SSc subtype.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 2,571 participants were included. Most were female (n = 2,241; 87%), and 38% (n = 976) had diffuse SSc. Mean (±SD) age was 54.9 (±12.7) years and duration since onset of first non-Raynaud phenomenon symptom was 10.8 (±8.7) years. MDC95 estimate was 0.41 points (95% CI 0.40–0.42) for the HAQ-DI, between 4.88 points (95% CI 4.72–5.05) and 9.02 points (95% CI 8.80–9.23) for the seven PROMIS-29v2.0 domains, and 5.16 points (95% CI 5.06–5.26) for the PHQ-8. MDC95 estimates were not materially different across subgroups.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>MDC95 and MDC90 estimates were precise and similar across age, sex, and SSc subtype groups. HAQ-DI MDC95 and MDC90 were substantially larger than previous estimates of HAQ-DI minimal important difference from several small studies. Minimally important differences of all measures should be evaluated in large studies using anchor-based methods.</p>\n </section>\n </div>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acr.25397","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arthritis Care & Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acr.25397","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Systemic sclerosis (SSc) is a rare, chronic autoimmune disorder associated with disability, diminished physical function, fatigue, pain, and mental health concerns. We assessed minimal detectable changes (MDCs) of the Health Assessment Questionnaire–Disability Index (HAQ-DI), Patient-Reported Outcomes Measurement Information System-29 Profile version 2.0 (PROMIS-29v2.0) domains, and Patient Health Questionnaire (PHQ)-8 in people with SSc.

Methods

Scleroderma Patient-Centered Intervention Network Cohort participants completed the HAQ-DI, PROMIS-29v2.0 domains, and PHQ-8 at baseline assessments from April 2014 until August 2023. We estimated MDC95 (smallest change that can be detected with 95% certainty) and MDC90 (smallest change that can be detected with 90% certainty) with 95% confidence intervals (CIs) generated via the percentile bootstrapping method resampling 1,000 times. We compared MDC estimates by age, sex, and SSc subtype.

Results

A total of 2,571 participants were included. Most were female (n = 2,241; 87%), and 38% (n = 976) had diffuse SSc. Mean (±SD) age was 54.9 (±12.7) years and duration since onset of first non-Raynaud phenomenon symptom was 10.8 (±8.7) years. MDC95 estimate was 0.41 points (95% CI 0.40–0.42) for the HAQ-DI, between 4.88 points (95% CI 4.72–5.05) and 9.02 points (95% CI 8.80–9.23) for the seven PROMIS-29v2.0 domains, and 5.16 points (95% CI 5.06–5.26) for the PHQ-8. MDC95 estimates were not materially different across subgroups.

Conclusion

MDC95 and MDC90 estimates were precise and similar across age, sex, and SSc subtype groups. HAQ-DI MDC95 and MDC90 were substantially larger than previous estimates of HAQ-DI minimal important difference from several small studies. Minimally important differences of all measures should be evaluated in large studies using anchor-based methods.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
系统性硬化症患者 HAQ-DI、PROMIS-29v2.0 和 PHQ-8 的最小可检测变化:SPIN 队列横断面研究》。
目的:系统性硬化症(SSc)是一种罕见的慢性自身免疫性疾病,与残疾、身体功能减退、疲劳、疼痛和心理健康问题有关。我们对 SSc 患者的健康评估问卷-残疾指数(HAQ-DI)、患者报告结果测量信息系统-29 档案 2.0 版(PROMIS-29v2.0)和患者健康问卷-8(PHQ-8)的最小可检测变化(MDC)进行了评估:硬皮病患者中心干预网络队列参与者在2014年4月至2023年8月的基线评估中完成了HAQ-DI、PROMIS-29v2.0域和PHQ-8。我们估算了 MDC95 和 MDC90,并通过百分位数引导法重新取样 1000 次,得出了 95% 的置信区间 (CI)。我们比较了不同年龄、性别和 SSc 亚型的 MDC 估计值:结果:共纳入 2,571 名参与者。大多数为女性(N = 2,241; 87%),38%(N = 976)患有弥漫性 SSc。平均(标清)年龄为 54.9 (12.7) 岁,自首次出现非雷诺现象症状以来的持续时间为 10.8 (8.7) 年。HAQ-DI的MDC95估计值为0.41点(95% CI:0.40至0.42),PROMIS-29v2.0的7个领域为4.88点(95% CI:4.72至5.05)至9.02点(95% CI:8.80至9.23),PHQ-8为5.16点(95% CI:5.06至5.26)。不同亚组的 MDC95 估计值没有实质性差异:结论:不同年龄、性别和 SSc 亚型组的 MDC95 和 MDC90 估计值精确且相似。HAQ-DI的MDC95和MDC90远大于之前几项小型研究对HAQ-DI最小重要差异的估计值。应在大型研究中使用基于锚的方法评估所有测量指标的最小重要差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
9.40
自引率
6.40%
发文量
368
审稿时长
3-6 weeks
期刊介绍: Arthritis Care & Research, an official journal of the American College of Rheumatology and the Association of Rheumatology Health Professionals (a division of the College), is a peer-reviewed publication that publishes original research, review articles, and editorials that promote excellence in the clinical practice of rheumatology. Relevant to the care of individuals with rheumatic diseases, major topics are evidence-based practice studies, clinical problems, practice guidelines, educational, social, and public health issues, health economics, health care policy, and future trends in rheumatology practice.
期刊最新文献
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction. Issue Information Area-level socioeconomic status impacts healthcare visit frequency by Australian inflammatory arthritis patients: results from the Australian Rheumatology Association Database. Building the OAChangeMap to improve the service delivery of the New South Wales Osteoarthritis Chronic Care Program: a worked example of using a co-design framework. Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood-Onset ANCA-Associated Vasculitis: An ARChiVe registry-cohort study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1